"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.

Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

Throughout the last three months, 9 analysts have evaluated Halozyme Therapeutics HALO, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...